A meta-analysis of five randomized controlled trials found that performing endovascular therapy with stent retrievers was safe and effective in managing acute ischemic stroke and led to a significant improvement in functional clinical outcomes compared with standard therapy.

Within two years following PCIs, 13.3 percent of subsequent scheduled noncardiac surgical procedures were cancelled, according to an analysis of all PCIs performed at the Veterans Affairs (VA) Healthcare System from fiscal year 2000 to 2010.

Boston Scientific announced on Oct. 8 that it had provided additional financing for MValve Technologies, a company that is developing a percutaneous mitral valve replacement system. Boston Scientific said it has an exclusive option to acquire MValve Technologies, a privately held corporation founded in 2011 with operations in San Diego and Herezeliya, Israel.

St. Jude Medical completed its acquisition of Thoratec on Oct. 8, expanding its heart failure business and adding products such as the HeartMate II left ventricular assist device.

From Oct. 11 to 15, leaders in interventional cardiovascular medicine will gather in San Francisco for the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Cardinal Health completed its acquisition of Johnson and Johnson’s Cordis business on Oct. 4 for $1.944 billion, seven months after Cardinal Health announced its offer.

Express Scripts announced it would include the two recently FDA-approved proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on its national preferred formulary, which covers approximately 25 million people in the U.S.

The FDA sent a warning letter to St. Jude Medical regarding a facility in Atlanta where the company manufactures its CardioMEMS heart failure system. St. Jude Medical revealed the information in an 8-K filing to the Securities and Exchange Commission on Oct. 1.

On Oct. 29 in Oakland, members of the California Technology Assessment Forum (CTAF) are expected to discuss and debate a report on the cost effectiveness of two recently FDA-approved heart failure treatments.

For the past few years, the Transcatheter Cardiovascular Therapeutic (TCT) conference has focused on structural heart disease as a major subspecialty in interventional cardiology. This year’s conference, which runs from Oct. 10 to 15 in San Francisco, will have more of an emphasis on coronary intervention, according to TCT co-director Gregg W. Stone, MD.

After receiving reports regarding reduced leaflet motion in some bioprosthetic aortic valves, the FDA announced on Oct. 5 that the agency is working with the American College of Cardiology, the Society of Thoracic Surgeons and device manufacturers to design clinical studies to evaluate the situation.

The FDA approved the Synergy bioabsorbable polymer drug-eluting stent system on Oct. 5 to treat coronary artery disease. The Synergy stent is the first FDA-approved bioabsorbable polymer drug-eluting stent system, according to Boston Scientific, its manufacturer. The stent was approved in Europe in 2012.